Annual Report 2015–2016

Recommendations

Info

NHMRC’s Corporate Plan 2015–2016 sets out the agency’s purposes, planned activities and performance for the period 2015–16 to 2018–19, and addresses capability, environment and risk oversight and management as required by the PGPA Act. NHMRC’s annual performance statements are prepared in accordance with the PGPA Act and are measured against the targets set out in the Corporate Plan. The scope and reach of NHMRC’s activities are broad, with the agency spanning a wide range of health topics in the various aspects of its work – from funding research to guideline development and advice. The overall purposes of NHMRC, supporting the agency’s mission of ‘working to build a healthy Australia’, can be summarised as follows. PART 2 Performance Report • Investment to fund high quality health and medical research and build research capability • Translation to support the translation of health and medical research into better health outcomes • Integrity to promote the highest ethical standards in health and medical research. Figure 3 NHMRC strategy for health and medical research WORKING TO BUILD A HEALTHY AUSTRALIA LEAD SUPPORT ENGAGE RESPOND Investment Create knowledge and build research capability by supporting the highest quality health and medical research and the best researchers Translation Support the translation of health and medical research into clinical practice, policy and health systems and the effective commercialisation of research discoveries Strategic priorities Key activities Integrity Maintain a strong integrity framework for research and guideline development, underpinning rigorous research and relevant and accurate guidelines and promoting community trust Healthier Australians Better clinical care Improved health care system Economic benefit through innovation and improved productivity 24 Annual Report of the National Health and Medical Research Council 2015–2016
OUTCOMES AND PROGRAM STRUCTURE Through NHMRC Portfolio Budget Statement Program 1.1, the Australian Government invests in health and medical research that is undertaken within a well-established ethical framework, to address national health priorities and improve the health of all Australians. The Program objectives for NHMRC are to: • support high quality health and medical research • boost dementia research • facilitate simplified and consistent health and medical research • support the translation of health and medical research • promote the highest ethical standards in health and medical research. The agency Portfolio Budget Statement 2015–16 outlines the NHMRC budgeted expenses and resources as shown in the table below. Table 2 Portfolio Budget Statement – NHMRC expenses and resources Expenses for Outcome 1 Outcome 1: Improved health and medical knowledge, including through funding research, translating research findings into evidence-based clinical practice, administering legislation governing research, issuing guidelines and advice for ethics in health and the promotion of public health. Budget* 2015–16 $’000 (a) Actual Expenses 2015–16 $’000 (b) Variation 2015–16 $’000 (a)-(b) Programme 1.1: Health and Medical Research Administered expenses Ordinary Annual Services (Appropriation Act No. 1) 840,583 840,583 - To the Medical Research Endowment Account (MREA) (859,026) (836,043) (22,983) Special accounts Medical Research Endowment Account (MREA) 845,780 815,215 30,565 Departmental expenses Departmental appropriation 1 40,255 39,123 1,132 Expenses not requiring appropriation in the Budget year 2 2,300 2,347 (47) Total for Programme 1.1 869,892 861,225 8,667 Total expenses for Outcome 1 - - - PART 2 Performance Report 2014-15 2015–16 Average Staffing Level (number) 197 187 10 * Portfolio Additional Estimates Statements 2015–16 1 Departmental Appropriation combines Ordinary annual services (Appropriation Act Nos. 1, 3 and 5) and Retained Revenue Receipts under section 74 of the PGPA Act 2013. 2 Expenses not requiring appropriation in the Budget year is made up of depreciation expense, amortisation expense, makegood expense and audit fees. Annual Report of the National Health and Medical Research Council 2015–2016 25
Page 1 and 2: National Health and Medical Researc
Page 3 and 4: A HEALTHY START TO LIFE NHMRC is co
Page 5 and 6: CONTENTS ABOUT THE REPORT V PART 1
Page 7 and 8: ABOUT THE REPORT This report was pr
Page 9 and 10: PART1 OVERVIEW Chief Executive Offi
Page 11 and 12: Structural review of NHMRC’s gran
Page 13 and 14: During the year the NHMRC Council e
Page 15 and 16: NHMRC’s strategy for health and m
Page 17 and 18: RESEARCH FUNDING EXPENDITURE Fundin
Page 19 and 20: PROMOTING EXCELLENCE THROUGH THE NH
Page 21 and 22: Award Recipient Institution Researc
Page 23 and 24: Award Recipient Institution Researc
Page 25 and 26: CASE STUDY “This research is desi
Page 27 and 28: ASSOCIATE PROFESSOR LEAH COSGROVE C
Page 29 and 30: PROFESSOR LOUISA JORM WESTERN SYDNE
Page 31: PART 2 PERFORMANCE REPORT Chief Exe
Page 35 and 36: INVESTMENT Goal 5: Participate in d
Page 37 and 38: TRANSLATION Goal 3: Develop public
Page 39 and 40: INVESTMENT Create knowledge and bui
Page 41 and 42: Table 3 Expenditure for Aboriginal
Page 43 and 44: Figure 6 Expenditure by Science and
Page 45 and 46: Targeted Calls for Research The out
Page 47 and 48: GOAL 2: SUPPORT THE HEALTH AND MEDI
Page 49 and 50: Table 11 People support outcomes fo
Page 51 and 52: GOAL 3: BOOST DEMENTIA RESEARCH Boo
Page 53 and 54: GOAL 4: SUPPORT COLLABORATIVE, MULT
Page 55 and 56: Target 4: Finalise collaborative re
Page 57 and 58: GOAL 6: SUPPORT RESEARCH THAT WILL
Page 59 and 60: GOAL 7: PROMOTE ACCESS TO AND USE O
Page 61 and 62: GOAL 8: IMPROVE THE GRANT APPLICATI
Page 63 and 64: TRANSLATION Support the translation
Page 65 and 66: NHMRC also established a separate a
Page 67 and 68: GOAL 2: SUPPORT THE TRANSLATION OF
Page 69 and 70: Target 6: Publish an updated Statem
Page 71 and 72: In early 2016, the NHMRC completed
Page 73 and 74: GOAL 3: DEVELOP PUBLIC AND ENVIRONM
Page 75 and 76: Public consultation will be underta
Page 77 and 78: GOAL 4: REMOVE BARRIERS TO COMMERCI
Page 79 and 80: Table 17 NHMRC commitments to resea
Page 81 and 82: Target 2: Improve processes for cli
Page 83 and 84:
GOAL 1: RETAIN HIGH ETHICAL STANDAR
Page 85 and 86:
GOAL 2: STRENGTHEN THE PROCESS FOR
Page 87 and 88:
Outcome 2: Strengthen the process f
Page 89 and 90:
Target 3: Review Ethical Guidelines
Page 91 and 92:
GOAL 4: ADMINISTER THE RESEARCH INV
Page 93 and 94:
PART 3 OPERATING ENVIRONMENT Legisl
Page 95 and 96:
CORPORATE GOVERNANCE Governance bod
Page 97 and 98:
• the Chief Medical Officer or th
Page 99 and 100:
The ERLC assesses applications for
Page 101 and 102:
EXTERNAL SCRUTINY JUDICIAL DECISION
Page 103 and 104:
In accordance with the RMF: • the
Page 105 and 106:
Table 19 Freedom of Information req
Page 107 and 108:
ACCOUNTABILITY PURCHASING AND PROCU
Page 109 and 110:
Table 21 Consultancy services let d
Page 111 and 112:
Complaints and their outcomes Of th
Page 113 and 114:
CORRECTION OF MATERIAL ERRORS IN PR
Page 115 and 116:
CASE STUDY The team studied diaphra
Page 117 and 118:
4 Part PEOPLE MANAGEMENT People 110
Page 119 and 120:
Table 24 NHMRC employee overview as
Page 121 and 122:
Consultations also raised the impor
Page 123 and 124:
LEARNING AND DEVELOPMENT NHMRC’s
Page 125 and 126:
Flexible workplace practices CASE S
Page 127 and 128:
PART 5 FINANCIAL REPORT Financial P
Page 129 and 130:
AGENCY RESOURCE STATEMENT Table 28
Page 131 and 132:
INDEPENDENT AUDITOR’S REPORT To t
Page 133 and 134:
PART 5 financial report Annual Repo
Page 135 and 136:
Statement of Financial Position as
Page 137 and 138:
Cash Flow Statement for the period
Page 139 and 140:
Administered Reconciliation Schedul
Page 141 and 142:
All new standards, amendments to st
Page 143 and 144:
Reporting of Administered Activitie
Page 145 and 146:
Income and Expenses Administered on
Page 147 and 148:
Note 3.2 Non-Financial Assets Note
Page 149 and 150:
Revaluations of non-financial asset
Page 151 and 152:
Note 3.3 Other Payables 2016 2015 $
Page 153 and 154:
Funding Note 5.1 Appropriations Not
Page 155 and 156:
Note 5.3 Cash Flow Reconciliation R
Page 157 and 158:
People and Relationships Note 6.1 P
Page 159 and 160:
Managing Uncertainties Note 7.1 Con
Page 161 and 162:
Note 7.2 Financial Instruments - Co
Page 163 and 164:
Note 7.3 Administered - Financial I
Page 165 and 166:
Other Information Note 8: Reporting
Page 167 and 168:
6 PART APPENDICES Appendix 1: Execu
Page 169 and 170:
Executive Director, Evidence, Advic
Page 171 and 172:
CHAIR OF NHMRC COUNCIL Chair Profes
Page 173 and 174:
Australian Capital Territory Dr Pau
Page 175 and 176:
Professor Michael Kidd AM Member wi
Page 177 and 178:
APPENDIX 3: RESEARCH COMMITTEE The
Page 179 and 180:
APPENDIX 5: EMBRYO RESEARCH LICENSI
Page 181 and 182:
APPENDIX 7: HEALTH INNOVATION ADVIS
Page 183 and 184:
APPENDIX 9: PUBLIC CONSULTATIONS Pu
Page 185 and 186:
IREG IRIISS JPco-fuND JPND MREA NAB
Page 187 and 188:
PGPA Rule Reference Part of Report
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
INDEX A Aboriginal and Torres Strai
Page 195 and 196:
Cancer 5, 66 National Evidence Base
Page 197:
S scholarships, 10, 39-41, 42 scien
show all

Annual Report 2015–2016

Create successful ePaper yourself

Delete template?

Save as template?